Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy

被引：0
|
作者：
S. Lautenschlaeger
C. Dumke
L. Exeli
H. Hauswald
R. Engenhart-Cabillic
F. Eberle
机构：
[1] Universitätsklinikum Marburg,Klinik für Strahlentherapie und Radioonkologie
[2] Marburg Ion-Beam Therapy Center (MIT),RNS Gemeinschaftspraxis
[3] St. Josefs-Hospital,Klinik für Radio
[4] Universitätsklinikum Heidelberg,Onkologie
来源：
Strahlentherapie und Onkologie | 2023年 / 199卷
关键词：
Radioresistant cancer; Salvage chemoradiation; Particle beam radiotherapy; RBE; Gastrointestinal cancers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：982 / 991
页数：9
相关论文
共 50 条
  • [21] Is neoadjuvant chemotherapy the optimal treatment for primary resectable pancreatic cancer?
    Wang, Yu-song
    [J]. HPB, 2020, 22 (05) : 790 - 790
  • [22] Comparing gemcitabine-based combination chemotherapy with gemcitabine alone in inoperable pancreatic cancer: A meta-analysis.
    Liang, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 335S - 335S
  • [23] Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial
    Koerkamp, B. Groot
    Janssen, Q. P.
    van Dam, J. L.
    Bonsing, B. A.
    Bos, H.
    Bosscha, K. P.
    Haberkorn, B. C. M.
    de Hingh, I. H. J. T.
    Karsten, T. M.
    Van der Kolk, M. B.
    Liem, M. S. L.
    Loosveld, O. J. L.
    Patijn, G. A.
    van Santvoort, H. C. M.
    de Vos-Geelen, J.
    van der Holt, B.
    Homs, M. Y. V.
    van Tienhoven, G.
    Besselink, M. G.
    Wilmink, H. W.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1323 - S1323
  • [24] Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy
    Nakai, Yousuke
    Isayama, Hiroyuki
    Sasaki, Takashi
    Sasahira, Naoki
    Tsujino, Takeshi
    Kogure, Hirofumi
    Yagioka, Hiroshi
    Yashima, Yoko
    Togawa, Osama
    Arizumi, Toshihiko
    Matsubara, Saburo
    Hirano, Kenji
    Tada, Minoru
    Omata, Masao
    Koike, Kazuhiko
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 (03) : 252 - 259
  • [25] Role of concurrent gemcitabine-based chemoradiation and regional nodal irradiation in the treatment of locally advanced pancreatic cancer - Response
    Li, CP
    Chao, Y
    Yen, SH
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (03): : 1009 - 1010
  • [26] Treatment patterns of gemcitabine-based chemotherapy in patients with de novo and recurrent advanced biliary tract cancer.
    Dayyani, Farshid
    Stirnadel-Farrant, Heide A.
    Hu, Jenny
    Lin, Yian
    Kebede, Nehemiah
    Valerio, Stephen J.
    Ahn, Daniel H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 454 - 454
  • [27] Is skeletal muscle a predictor of toxicity in pancreatic cancer patients on gemcitabine-based chemotherapy regimens?
    Freckelton, J.
    Croagh, D.
    Holt, D. Q.
    Fox, A.
    Wong, R.
    Moore, G. T.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 58 - 58
  • [28] PROGNOSTIC IMPLICATION OF GEMCITABINE-BASED CHEMOTHERAPY AND INTRAOPERATIVE RADIATION THERAPY IN UNRESECTABLE PANCREATIC CANCER
    Fujii, T.
    Nagai, S.
    Kanda, M.
    Kodera, Y.
    Sahin, T. T.
    Sugimoto, H.
    Nomoto, S.
    Takeda, S.
    Nakao, A.
    Morita, S.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 263 - 263
  • [29] A prospective randomized trial on two gemcitabine-based regimens of chemotherapy for unresectable pancreatic cancer
    Popiela, T
    Kulig, J
    Sierzega, M
    Legutko, J
    [J]. GASTROENTEROLOGY, 2005, 128 (04) : A109 - A109
  • [30] Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy
    Chen, Yang
    Shi, Yan
    Yan, Huan
    Wang, Yan Rong
    Dai, Guang Hai
    [J]. ONCOTARGET, 2017, 8 (39) : 66593 - 66600
12345